Cart
sales@molnova.com
DDRI-18
CAS No. 4402-18-0
DDRI-18( —— )
Catalog No. M33980 CAS No. 4402-18-0
DDRI-18 is a novel small molecule inhibitor that regulates the DNA damage response with sensitizing and anticancer activities, inhibits non-homologous end-joining (NHEJ) DNA repair and enhances the cytotoxicity of anticancer DNA damage compounds.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 459 | In Stock |
|
| 10MG | 657 | In Stock |
|
| 25MG | 1026 | In Stock |
|
| 50MG | 1386 | In Stock |
|
| 100MG | 1832 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 3655 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDDRI-18
-
NoteResearch use only, not for human use.
-
Brief DescriptionDDRI-18 is a novel small molecule inhibitor that regulates the DNA damage response with sensitizing and anticancer activities, inhibits non-homologous end-joining (NHEJ) DNA repair and enhances the cytotoxicity of anticancer DNA damage compounds.
-
DescriptionDDRI-18 is a DNA damage response inhibitor that inhibits the non-homologous end-joining (NHEJ) DNA repair process. DDRI-18 is an effective chemosensitizing agent.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetDNA/RNA Synthesis
-
RecptorDNA/RNA Synthesis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number4402-18-0
-
Formula Weight416.48
-
Molecular FormulaC26H20N6
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESNC=1C=C(C=2NC=3C(N2)=CC=C(C3)C=4C=C5C(=CC4)N=C(N5)C6=CC(N)=CC=C6)C=CC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. D W Jun, et al. Characterization of DDRI-18 (3,3'-(1H,3'H-5,5'-bibenzo[d]imidazole-2,2'-diyl)dianiline), a novel small molecule inhibitor modulating the DNA damage response. Br J Pharmacol. 2012 Sep;167(1):141-50. ?
molnova catalog
related products
-
DMT-dU-CE Phosphoram...
DMT-dU-CE Phosphoramidite is a nucleoside molecule commonly used for the synthesis and sequencing of DNA.
-
JH-RE-06
JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing the recruitment of mutagenic POLζ. JH-RE-06 is an effective REV1-REV7 interface inhibitor (IC50=0.78 μM; Kd=0.42 μM), which targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 also improves chemotherapy.
-
Tallimustine HCl
Tallimustine HCl is a DNA inhibitor, an AT-specific alkylated antitumor derivative of diamycin.Tallimustine HCl can be used in severe combined immunodeficiency mouse models of adult myelogenous leukemia, which can be used for the treatment of leukemia.
